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W ITH THE INCREASING complexity 
of patients undergoing transplanta-
tion, the transplant services are called on to 
evaluate a variety of patients with concomi-
tant metabolic derangements. Optimal func-
tion of an allograft and management of these 
patients in the posttransplant period may 
require consideration of multiorgan trans-
plantation. The concept of multiorgan trans-
plantation has become a reality. Combined 
pancreas-kidney transplantation was the first 
example of this. Thereafter, combined heart-
kidney, heart-lungs, and heart-liver trans-
plants have been reported. In each instance, 
the combined transplants have been per-
formed in order to assure long-term allograft 
function by correcting coexisting dysfunction 
of other organ systems. 
A number of liver transplant candidates 
will have preexisting renal dysfunction, either 
secondary to renal flow abnormalities, drug 
toxicity, or secondary to an intrinsic renal 
defect. eg, interstitial nephritis, glomerulo-
nephritis, polycystic renal disease.1,2 While 
correction of secondary renal dysfunction can 
be expected in the former group, the post-
transplant management in the latter group is 
complicated by the necessity for adjustments 
in the immunosuppressive regimens.3 Thus, if 
chronic renal disease can be documented 
before hepatic transplantation, combined 
liver-kidney transplantation should be consid-
ered. In this report, we address combined 
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liver-kidney transplantation, with particular 
attention to the apparent phenomenon of pro-
tection of kidney allografts to antibody 
mediated destruction by liver allografts. 
MATERIALS AND METHODS 
During the period from July 1984 to August 1987, 12 
patients received combined liver-kidney transplants from 
single donors. Table I lists the clinical data of these 
patients as well as the results of the initial lymphocytO-
toxic crossmatches. The donor specific crossmatches and 
panel reactive antibody levels (%PRA) were performed as 
previously outlined.4 Detailed immunologic analysis of 
the four patients with strongly positive crossmatches are 
now presented. 
Serum samples were collected from all four patients 
before, during, and following the combined liver-kidney 
transplant procedures. For purposes of this paper, pre-
transplant serum was designated. pre-OT /KT; the 18JI1-
pie taken following liver revascularization, but before 
kidney transplantation is designated, pre-KT/post-OT; 
and those samples taken following completion of the 
combined transplant designated, post-OT /KT. 
Demonstration of the nature of the Iymphocytotoxic 
antibodies present in the sera of the strongly reactive, 
positive crossmatched patients was accomplished by solid 
phase immunoabsorptions, as previously described.' 
OKT3 levels were determined by enzyme linked immu-
noassay.) 
RESULTS 
Of the 12 patients undergoing combined 
liver-kidney transplantation, nine are alive 
during the follow-up period of 1 month to 36 
months. Of the three deaths, two deaths 
occurred in retransplanted patients, one dying 
of fungemia, and the other of generalized 
sepsis within the first month following 
retransplantation. The other patient died 4 
months following combined liver-kidney 
transplantation with good renal function until 
his death. 
Of the remaining nine patients, one patient 
(no. 8), who had a positive crossmatch pre-
transplant, but had evidence of renal flow 
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Table 1. ease Materiel 
PIIIient eau. of Organ I)ysfunctoin Preoperative Evaluation 
No .. Age/Sex L_ Kidney Serum Cr CrCI Croumatch 
1 44/F Polycystic Polycystic 2 20 Negative 
2 15/F Polycystic Polycystic 10· 0 Doubtful positive 
3 43/F PBC GN 4 20 Strong positive 
4 39/F Rejection Unknown 6 10 Negative 
5 381M Cirrhosis GN 4 10 Negative 
6 341M Cirrhosis GN I' 2.1 30 Doubtful positive 
7 56/M Etoh cirrhosis GN 3.5 NO Strong positive 
8 121M Cysteamine toxicity Cystinosis 6 5 Strong positive 
9 151M Rejection GN 2.5 28 Doubtful positive 
10 61/M Sclerosing cholengitis Interstitial nephritis 4.2 NO Negative 
11 48/M Etoh cirrhosia Unknown 10.8 o· Negative 
12 331M Failed ellOIP"aft Unknown 3.3 NO Strong positive 
Abbreviation: GN. glomerulonephritis. 
"On dialysiS. 
witbout function, eventually required dialysis 
and a second kidney transplant. In this 
patient, the kidney perfused well following the 
iiver transplant, although urine function was 
. educed. Renal function remained depressed 
In this patient, although renal flow scans 
revealed fair blood flow to the allograft. Mul-
tiple biopsies of this allograft revealed tubular 
injury without evidence of humorally me-
diated injury. The remaining eight patients 
have shown good renal function in the post-
transplant period. 
As shown in Table 1, four patients (nos. 3, 
1, 8, and 12) were found to have a positive 
CTossmatch before the liver phase of the com-
bined transplant (pre-OT/KT samples). 
These positive crossmatches were due entirely 
wanti-HLA class I antibodies, as demon-
trated by their removal by immunoabsorp-
[ion on pololed platelets. In three of these 
patients, post-OT/pre-KT samples showed a 
conversion to a negative crossmatch (in the 
fourth patient this was not done, no. 8). A 
kidney allograft, harvc:sted from the same 
donor, was then placed into the recipient, and 
in patients no. 3, 7, and 12, good initial 
function was noted. In none of these patients 
was there evidence of hyperacute rejection. 
Post-OT /KT samples were collected in 
patients no. 3, 7, and 8, and then analyzed for 
the reappearance of donor specific lymphocy· 
totoxic antibodies in the posttransplant period 
(data on patient no. 12 was not available at 
the time of preparation). Lymphocytotoxic 
antibodies with donor specificity could not be 
detected in any of the samples during the first 
week posttransplant. 
In all three patients, no. 3,1 and 8, allograft 
dysfunction due to rejection was treated with 
the mouse anti-human T cell monoclonal anti-
body, OKT3, during the second to fourth 
posttransplant week. During this time, when 
detectable levels of OKT3 could be demon-
strated, a nonspecific lymphocytoxicity could 
be demonstrated. This nonspecificity was due 
to the nature of the administered monoclonal 
antibody, since OKT3 binds to human T cells 
and fixes complement leading to cytotoxicity. 
Absorptions of the administered OKT3 was 
done on solid-phase anti-mouse immuno-
globulin beads. This led to removal of lympho-
cytotoxicity to background levels. Table 2 
demonstrates an example in patient no. 3, 
where immunoabsorption of OKT3, found in 
quantitated levels in the serum, led to both 
negative crossmatches and a return of the 
%PRA to what would be expected. 
The decrease in %PRA and conversion of a 
positive to negative crossmatch following liver 
transplantation was correlated to the HLA 
specificit)l of the antibody found in the pre-
transplant serum and the HLA type of the 
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Table 2. Patient No.3 Cro"lIIIItch. " PRA. end OKT3 Level. 
'? 
Serum Unabeabed Val ... 
5amI)1e c)('PRA er-.tdI 
Pr&-OT/KT 94 + 
Post-OT /pre-KT 48 
Post-OT/KT 
Day 2 50 
Day 3 48 
Day 5 NO 
Day 6 50 
Day 7 52 
Day 9 76 + 
Day 12 94 + 
Day 13 96 + 
Day 14 96 + 
Day 15 96 + 
Day 16 94 + 
Day 19 92 + 
Day 20 92 + 
Day 22 56 
Day 24 36 
Polyvalent 100 + 
OKT3 standard 100 + 
Normal 0 
• Absorbed on solid phase anti-mouse IgG immunoabaorbent. 
transplanted organs. In the two instances 
where an HLA specificity could be deter-
mined by panel analysis, transplantation with 
donor organs bearing these HLA specificities 
led to a specific disappearance of these anti-
bodies during the posttransplant phase. 
DISCUSSION 
In 1970, Simpson et ai, first explored the 
notion of protection of renal allografts by 
using vascularized hepatic allografts from the 
same donor.s Other investigators have also 
implied a protective role of the donor liver in 
inducing a degree of protection toward other 
tissues.6,7 While we cannot draw any conclu-
sions regarding any protective effect of the 
liver allograft on the renal allograft in cell 
mediated rejection, we have presented evi-
dence to suggest a role of the liver in removal 
of preformed lymphocytotoxic antibodies. 
The procedure of combined liver-kidney 
transplantation appears to be safe, with two 
deaths occurring in patients being retrans-
planted for combined liver and kidney dys-
~v .... • OKT3leve1 
%PRA CroumMdl (ng/mi.) 
94 + 0 
46 0 
50 0 
48 0 
NO 0 
50 0 
52 0 
52 100 
42 330 
46 330 
40 1.100 
44 1.700 
42 1.600 
38 2.200 
32 1,200 
38 0 
36 0 
100 + 0 
0 2,500 
0 0 
function, with historically poorer prognosis. In 
the remaining ten patients, the presence of a 
well functioning kidney allowed the transplant 
team to use therapeutic levels of cyclosporine 
A, without fear of further damage to compro-
mised kidneys. 
The mechanism of this apparent protective 
effect of the liver on preformed antibody 
states is not clear. The relative resistance of 
the liver allograft to antibody damage is well 
known.s Whether this is due to the unique 
anatomic architecture of the liver or whether 
it is able to "neutralize" the cytotoxic antibod-
ies is not clear. 
With the increasing use of anti-human T 
cell monoclonal antibodies in the treatment of 
rejection, the interpretation of crossmatch or 
%PRA in samples with potential levels of 
these antibodies, must be made cautiously. 
Confirmation of the nature of the Iymphocy-
totoxic antibodies by specific immune-
absorptions must be done in order to avoid 
potentially conferring a label of a "positive 
crossmatch" on a transplant recipient await-
ing another transplant. 
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